Table 5.
Safety outcomes of patients with combined treatment or medication treatment in one-year follow-up
| Safety measure | No. (%) | |||
|---|---|---|---|---|
| Combined treatment (n=633) |
Medication treatment (n=635) |
χ2 Testa | p Value |
|
| Adverse events | ||||
| Extrapyramidal symptoms | 135(21.3) | 142(22.4) | 0.199 | 0.66 |
| Hypersomnia, sleepiness | 202(31.9) | 216(34.0) | 0.635 | 0.43 |
| Dry month, constipation, Urinary hestitancy | 277(43.8) | 301(47.4) | 1.695 | 0.19 |
| Menstrual irregularitiesb | 46(15.9) | 47(16.7) | 0.068 | 0.79 |
| Dizziness | 76(12.0) | 82(12.9) | 0.239 | 0.63 |
| Insomnia | 35(5.5) | 50(7.9) | 2.787 | 0.10 |
| Weight gain>7% (from baseline to last observation) | 149 (23.5) | 132 (20.8) | 1.391 | 0.24 |
| Medication added | ||||
| Lithium/anticonvulsants | 15(2.4) | 20(3.1) | 0.718 | 0.40 |
| Antidepressants | 49(7.7) | 58(9.1) | 0.796 | 0.37 |
| Anxiolytics | 35(5.5) | 40(6.3) | 0.338 | 0.56 |
| Anticholinergic agents | 161(25.4) | 176(27.7) | 0.846 | 0.36 |
| β-Adrenergic receptor antagonists | 41(6.5) | 54(8.5) | 1.879 | 0.20 |
| Other drugs | 41(6.5) | 40(6.3) | 0.017 | 0.91 |
a
χ2 for categorical variables
b
Percentages are based on the number of female patients: 289 in combined treatment group and 281 in medication treatment group.